We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “Sodium-glucose transport protein 2 (SGLT2) inhibitor ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The use of SGLT2 inhibitors and GLP-1 receptor agonists ...

The study covered in this summary is under consideration at Cardiovascular Diabetology and was published on researchsquare.com as a preprint and has not yet been peer reviewed. Patients with type 2 ...

Use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors rather than metformin as first-line treatment for type 2 diabetes appears to cut the risk for heart failure hospitalization but not myocardial ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed. The combined 12-month risk for myocardial infarction (MI), ...

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

In a recent study published in the journal Signal Transduction and Targeted Therapy, researchers from Australia investigated the potential of small molecule inhibitors, specifically GSK126 (short for ...